Experience with the long-acting somatostatin analogue Octreotide in the treatment of castrate-resistant prostate cancer
Abstract
To treat castration-resistant prostate cancer (CRPC) is one of the most complex problems in urologic oncology.
A total of 184 patients with CRPC treated with the long-acting somatostatin analogue octreotide depot have been followed up since 2010.
The efficacy and tolerability of the drug at doses of 20 and 30 mg were compared. The 30-mg group showed a high efficiency – a positive response in almost 80% of the patients.
The larger dose of the agent caused no additional adverse reactions.
The administration of the long-acting somatostatin analogue gives rise to an objective effect, allowing the initiation of chemotherapy and other expensive treatments for CRPC to be postponed.
The Di Bella's Method: Use of Somatostatin analogue Octreotide and/or derivatives and pseudo-Metronomic Chemotherapy (together with others chemical compounds) in Prostate Cancer:
See also:
- Official Web Site: The Di Bella Method;
- Somatostatin in oncology, the overlooked evidences - In vitro, review and in vivo publications;
- Publication, 2018 Jul: Over-Expression of GH/GHR in Breast Cancer and Oncosuppressor Role of Somatostatin as a Physiological Inhibitor (from Di Bella's Foundation);
- Publication, 2019 Aug: The Entrapment of Somatostatin in a Lipid Formulation: Retarded Release and Free Radical Reactivity (from Di Bella's Foundation);
- Publication, 2019 Sep: Effects of Somatostatin and Vitamin C on the Fatty Acid Profile of Breast Cancer Cell Membranes (from Di Bella's Foundation);
- Publication, 2019 Sep: Effects of somatostatin, curcumin, and quercetin on the fatty acid profile of breast cancer cell membranes (from Di Bella's Foundation);
- Publication, 2020 Sep: Two neuroendocrine G protein-coupled receptor molecules, somatostatin and melatonin: Physiology of signal transduction and therapeutic perspectives (from Di Bella's Foundation);
- The Di Bella Method (A Fixed Part - Bromocriptine and/or Cabergoline);
- Prolactin inhibitors in oncology - In vitro, review and in vivo publications;
The Di Bella's Method: Use of Somatostatin analogue Octreotide and/or derivatives - together with others chemical compounds - in several Oncological Pathologies:
- Large B-cells Non-Hodgkin's Lymphoma, Stage IV-AE: a Case Report;
- Non-Hodgkin's Lymphoma, Stage III-B-E: a Case Report;
- Pancreatic Adenocarcinoma: clinical records on 17 patients treated with Di Bella's Method;